KROS — Keros Therapeutics Share News
0.000.00%
Last trade - 00:00- $223.65m
- -$33.96m
- $244.06m
Brief: Keros Therapeutics Announces Additional Update On The Phase 2 Tropos Trial
Keros Therapeutics drops on halting lung disease trial on safety concerns
Keros halts blood pressure treatment trial on safety issues (updated)
Keros halts hypertension treatment trial on safety issues
U.S. STOCKS ON THE MOVE-Teradyne, Keysight Technologies, Ametek
Guggenheim downgrades Keros Therapeutics to 'neutral'
U.S. RESEARCH ROUNDUP-Amazon, Ford, Netflix
U.S. STOCKS ON THE MOVE-Constellation Energy, Costco, ServiceTitan
U.S. STOCKS ON THE MOVE-Riot Platforms, Archer, J.Jill
Keros Therapeutics hits all-time low as safety concerns halt trial dosing
U.S. STOCKS ON THE MOVE-Chewy, Centene, General Dynamics
U.S. STOCKS ON THE MOVE-Adobe, Nordson, Keros Therapeutics
Brief: Keros Therapeutics Announces Update On The Phase 2 Tropos Trial
Keros Therapeutics halts dosing of blood pressure treatment after safety review (updated)
Keros Therapeutics plunges as dosing halted in trial due to safety concerns
Keros Therapeutics voluntarily halts dosing of blood pressure treatment after safety review
U.S. STOCKS ON THE MOVE-PSQ Holdings, Core Scientific, Keros
Keros rises after blood cancer drug license deal with Takeda
Cautious uptake of Merck's Winrevair gives opportunity to rivals, Oppenheimer says